Research programme: Parkinson's disease therapeutics - Congruence Therapeutics
Alternative Names: CGX program 2 - Congruence TherapeuticsLatest Information Update: 30 Jun 2023
At a glance
- Originator Congruence Therapeutics
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 04 Jun 2023 Early research in Parkinson's disease in Canada (unspecified route) (Congruence Therapeutics pipeline, June 2023)
- 04 Jun 2023 Early research in Unspecified in Canada (unspecified route) (Congruence Therapeutics pipeline, June 2023)